JP2023110094A5 - - Google Patents

Download PDF

Info

Publication number
JP2023110094A5
JP2023110094A5 JP2023096315A JP2023096315A JP2023110094A5 JP 2023110094 A5 JP2023110094 A5 JP 2023110094A5 JP 2023096315 A JP2023096315 A JP 2023096315A JP 2023096315 A JP2023096315 A JP 2023096315A JP 2023110094 A5 JP2023110094 A5 JP 2023110094A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
lymphoma
leukemia
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023096315A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023110094A (ja
JP7521070B2 (ja
Filing date
Publication date
Priority claimed from JP2020544852A external-priority patent/JP7317032B2/ja
Application filed filed Critical
Publication of JP2023110094A publication Critical patent/JP2023110094A/ja
Publication of JP2023110094A5 publication Critical patent/JP2023110094A5/ja
Priority to JP2024111017A priority Critical patent/JP2024138421A/ja
Application granted granted Critical
Publication of JP7521070B2 publication Critical patent/JP7521070B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023096315A 2018-02-27 2023-06-12 Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体 Active JP7521070B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024111017A JP2024138421A (ja) 2018-02-27 2024-07-10 Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862635834P 2018-02-27 2018-02-27
US62/635,834 2018-02-27
JP2020544852A JP7317032B2 (ja) 2018-02-27 2019-02-27 Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体
PCT/US2019/019856 WO2019169001A1 (en) 2018-02-27 2019-02-27 Chromene derivatives as inhibitors of tcr-nck interaction

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020544852A Division JP7317032B2 (ja) 2018-02-27 2019-02-27 Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024111017A Division JP2024138421A (ja) 2018-02-27 2024-07-10 Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体

Publications (3)

Publication Number Publication Date
JP2023110094A JP2023110094A (ja) 2023-08-08
JP2023110094A5 true JP2023110094A5 (enExample) 2023-09-11
JP7521070B2 JP7521070B2 (ja) 2024-07-23

Family

ID=65724589

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544852A Active JP7317032B2 (ja) 2018-02-27 2019-02-27 Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体
JP2023096315A Active JP7521070B2 (ja) 2018-02-27 2023-06-12 Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体
JP2024111017A Pending JP2024138421A (ja) 2018-02-27 2024-07-10 Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020544852A Active JP7317032B2 (ja) 2018-02-27 2019-02-27 Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024111017A Pending JP2024138421A (ja) 2018-02-27 2024-07-10 Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体

Country Status (16)

Country Link
US (5) US10696663B2 (enExample)
EP (1) EP3759086A1 (enExample)
JP (3) JP7317032B2 (enExample)
KR (1) KR20200140262A (enExample)
CN (2) CN117304157A (enExample)
AU (2) AU2019229258B2 (enExample)
BR (1) BR112020017386A2 (enExample)
CA (1) CA3091202A1 (enExample)
CO (1) CO2020010537A2 (enExample)
EA (1) EA202091742A1 (enExample)
IL (2) IL301120B2 (enExample)
MX (2) MX2020008814A (enExample)
PH (1) PH12020500638A1 (enExample)
SG (1) SG11202008067QA (enExample)
WO (1) WO2019169001A1 (enExample)
ZA (1) ZA202310843B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117304157A (zh) 2018-02-27 2023-12-29 阿塔克斯生物制药有限公司 作为tcr-nck相互作用的抑制剂的色烯衍生物
WO2025137442A1 (en) * 2023-12-22 2025-06-26 Artax Biopharma Inc. SOLID AND SALT FORMS OF TCR-NcK MODULATORS AND USES THEREOF

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
FR2772761B1 (fr) * 1997-12-23 2000-05-26 Lipha Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant
PT1230232E (pt) 1999-11-05 2004-07-30 Cytovia Inc 4h-cromeno substituido e seus analogos como activadores de caspases e indutores de apoptose e sua utilizacao
UA72290C2 (uk) 1999-12-10 2005-02-15 Пфайзер Продактс Інк. СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ)
WO2002008217A2 (en) 2000-07-21 2002-01-31 Chugai Seiyaku Kabushiki Kaisha COUMARIN DERIVATIVES USEFUL AS TNFα INHIBITORS
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
US7015328B2 (en) 2001-05-16 2006-03-21 Cytovia, Inc. Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6927224B2 (en) * 2001-08-11 2005-08-09 Bristol Myers Squibb Company Selective estrogen receptor modulators
WO2003062272A1 (es) 2002-01-24 2003-07-31 Consejo Superior De Investigaciones Científicas Nueva estrategia moduladora de la activacion de los linfocitos t basada en la regulación de la interaccion cd3e- nck.
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7476741B2 (en) 2002-05-16 2009-01-13 Cytovia, Inc. Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP2055310B1 (en) 2002-08-14 2015-12-16 Silence Therapeutics GmbH Protein kinase N beta for the diagnosis and the treatment of late stage tumor
BRPI0409063A (pt) 2003-04-03 2006-03-28 Semafore Pharmaceuticals Inc pró medicamentos de inibidor de pi-3 cinase
BRPI0410870A (pt) 2003-05-30 2006-07-04 Gemin X Biotechnologies Inc compostos trieterocìclicos, composições, e métodos para tratar cáncer ou doenças virais
CN100577680C (zh) 2003-07-03 2010-01-06 宾夕法尼亚大学理事会 对Syk激酶表达的抑制
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
KR101533268B1 (ko) 2005-05-12 2015-07-03 애브비 바하마스 리미티드 아폽토시스 촉진제
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
EP1931645B1 (en) 2005-10-07 2014-07-16 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0607389D0 (en) 2006-04-12 2006-05-24 Novartis Ag Organic compounds
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
CN101861313B (zh) 2007-03-12 2014-06-04 Ym生物科学澳大利亚私人有限公司 苯基氨基嘧啶化合物及其用途
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2009022633A1 (ja) * 2007-08-10 2009-02-19 Astellas Pharma Inc. 二環式アシルグアニジン誘導体
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
ES2331451B1 (es) 2008-06-30 2010-10-21 Consejo Superior De Investigaciones Cientificas (Csic) Inmunosupresor basado en la interrupcion de la interaccion tcr-nck.
WO2010009069A1 (en) 2008-07-16 2010-01-21 Bristol-Myers Squibb Company Chromene modulators of chemokine receptor activity
ES2334318B2 (es) 2008-09-05 2011-11-28 Universidad Politécnica de Madrid Sistema de deteccion optica para bio-ensayos de alta sensibilidad sinmarcado.
JP5578083B2 (ja) 2008-12-05 2014-08-27 アステラス製薬株式会社 ２ｈ−クロメン化合物及びその誘導体
ES2379242B1 (es) * 2010-09-28 2013-03-04 Consejo Superior De Investigaciones Científicas (Csic) Derivados de cromeno.
CN103841969A (zh) * 2011-08-04 2014-06-04 美国卫生和人力服务部 经由药物介导的对类二十烷酸平衡的操作治疗和预防微生物介导的疾病
EP2693164A1 (en) 2012-08-03 2014-02-05 Universidad Politécnica de Madrid Interferometric detection method
ES2534318B1 (es) 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno sustituidos por alcóxido como inhibidores de la interacción TCR-Nck
ES2534336B1 (es) 2013-10-18 2016-01-28 Artax Biopharma Inc. Derivados de cromeno como inhibidores de la interacción TCR-Nck
US9968604B2 (en) * 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
CN104844471B (zh) * 2015-04-21 2017-05-03 苏州远智医药科技有限公司 一种作为dor受体拮抗剂的化合物
CN117304157A (zh) 2018-02-27 2023-12-29 阿塔克斯生物制药有限公司 作为tcr-nck相互作用的抑制剂的色烯衍生物

Similar Documents

Publication Publication Date Title
JP2023110094A5 (enExample)
Li et al. Ferroelectric phase diagram of PVDF: PMMA
Scherman et al. Olefin metathesis and quadruple hydrogen bonding: A powerful combination in multistep supramolecular synthesis
CN104955456A (zh) 作为分拣蛋白抑制剂的n-取代的-5-取代的邻氨甲酰苯甲酸
Petro et al. Microwave Absorption and Molecular Structure in Liquids. XX. Dielectric Relaxation Times and Molecular Shapes of Some Substituted Benzenes and Pyridines1-3
JP2020537671A5 (enExample)
Pal et al. Comparison of dipolar, H-bonding, and dispersive interactions on gelation efficiency of positional isomers of keto and hydroxy substituted octadecanoic acids
Eccles et al. Investigating C S··· I Halogen Bonding for Cocrystallization with Primary Thioamides
Schwab et al. Synthesis and Structure of Trigonal and Tetragonal Connectors for a “Tinkertoy” Construction Set
Jia et al. Insights into intermolecular interactions of spironolactone solvates
IL276887B2 (en) Novel chromium as inhibitors of tcr–nck interaction
Koizumi et al. Crystallization technique of high-quality protein crystals controlling surface free energy
Dessipri et al. Fluorinated Poly (α, l-glutamate) s
JPWO2019169001A5 (enExample)
Fouda et al. Discovery, synthesis, and in vitro characterization of 2, 3 derivatives of 4, 5, 6, 7-tetrahydro-benzothiophene as potent modulators of retinoic acid receptor-related orphan receptor γt
Davidson et al. Halogen Bonding in Bicomponent Monolayers: Self-Assembly of a Homologous Series of Iodinated Perfluoroalkanes with Bipyridine
Chimatahalli Shanthakumar et al. Unveiling a Novel Solvatomorphism of Anti-inflammatory Flufenamic Acid: X-ray Structure, Quantum Chemical, and In Silico Studies
Vij et al. Structures of the BrF4+ and IF4+ Cations
Pelzer et al. Synthesis and Characterization of Tetrakis (pentafluoroethyl) germane
JPH05214078A (ja) プロペランを含むコポリマー及びそれより製造されるコンタクトレンズ
Brand et al. Sterically constrained tricyclic phosphine: redox behaviour, reductive and oxidative cleavage of P–C bonds, generation of a dilithium phosphaindole as a promising synthon in phosphine chemistry
Syrovaya et al. Investigation of quantum-chemical properties of meloxicam
JPH024722A (ja) 弗素含有環状オレフィン化合物及びその製法
Gascoin et al. Synthesis and Characterization of Cs5In3As4 with a Structure of Two Coexisting “Polymorphic” Forms of Different Dimensionality
Ito et al. Topochemical studies. VII. The crystal and molecular structures of tetrachlorophthalic acid hemihydrate and tetrabromophthalic anhydride.